

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number
WO 02/05843 A2

(51) International Patent Classification⁷: **A61K 39/00**

1049 Cortland Avenue, San Francisco, CA 94110 (US).
LI, Danxi [US/US]; 90 Behr Avenue, #32, San Francisco,
CA 94131 (US).

(21) International Application Number: **PCT/US01/22555**

(74) Agents: ANDERTON, Tom et al.; Exelixis, Inc., 170 Harbor Way, South San Francisco, CA 94083-0511 (US).

(22) International Filing Date: 18 July 2001 (18.07.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): EX-ELIXIS, INC. [US/US]; 170 Harbor Way, P.O. Box 511, South San Francisco, CA 94083-0511 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

Published:

(75) Inventors/Applicants (*for US only*): FRIEDMAN, Lori [US/US]; One Bayside Village Place, Unit 212, San Francisco, CA 94107 (US). LARSON, Jeffrey, S. [US/US]; 1220 El Camino Real, #305, Burlingame, CA 94010 (US). BELVIN, Marcia [US/US]; 1619 Walnut Street, Apt. C, Berkeley, CA 94709 (US). CHEN, Changyou [US/US]; 6465 Crestwood Drive, Castro Valley, CA 94552 (US). ROBERTSON, Stephanie, A. [US/US]; 255 Fowler Avenue, San Francisco, CA 94127 (US). LIOUBIN, Mario [US/US]; 3014 Los Prados, #A310, San Mateo, CA 94403 (US). SHI, Wen [US/US]; 1324 8th Avenue, #4, San Francisco, CA 94112 (US). CHAN, Jocelyn [US/US];

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

A2

WO 02/05843

(54) Title: HUMAN RRP SEQUENCES AND METHODS OF USE

(57) Abstract: Rhomboid Related Proteins (RRPs), involved in the EGFR signaling pathway, are provided. Transgenic, nonhuman mammals containing a transgene encoding an RRP polypeptide or a gene effecting the expression of an RRP polypeptide, along with methods of modulating the interaction of RRP proteins with their pathway members, and methods of screening for agents that modulate the interaction of an RRP polypeptide with an RRP binding target, such as RRP-specific antibodies and small molecules identified in high throughput screens, are also provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein.

BEST AVAILABLE COPY

HUMAN RRP SEQUENCES AND METHODS OF USE

REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. provisional patent applications 60/219,289
5 filed 7/19/2000, 60/277,487 filed 3/21/2001, 60/277,471 filed 3/21/2001, and application
no. ____/_____, entitled "Human RRP Sequences and Methods of Use" filed 7/12/2001, the
contents of which are hereby incorporated in their entirety.

BACKGROUND OF THE INVENTION

10 Signal transduction pathways are made up of growth factors, their receptors,
upstream regulators of the growth factors, and downstream intracellular kinase networks.
These pathways regulate many cellular processes, including proliferation, and appear to
play a key role in oncogenesis.

15 The epidermal growth factor receptor (EGFR) and its pathway members are among
the most widely explored signaling pathways. Signaling through this pathway elicits
diverse biological responses whose manifestations can include mitogenesis or apoptosis,
enhanced cell motility, protein secretion, and differentiation or dedifferentiation. Up-
regulated EGFR signaling has been implicated in organ morphogenesis, maintenance and
repair, and is correlated with invasion and metastasis of many types of tumors. Thus,
20 EGFR and its pathway signaling members are targets for therapeutic intervention in
wound repair and cancer.

Signal transduction pathways, such as the EGFR pathway, are evolutionarily
conserved among species as distant as the worm *Caenorhabditis elegans*, the fruit fly
Drosophila melanogaster, and vertebrates (Duffy JB, and Perrimon N, Curr. Opin. Cell
25 Biol. (1996) 8:231-238). In fact, ligands for the *Drosophila* EGFR (DER), known as Spitz
(Rutledge B, et al, Genes Dev. (1992) 6:1503-1517) and Gurken (Neuman-Silberberg FS,
and Schupbach T, Cell (1993) 75:165-174), are both similar to TGF α (transforming
growth factor alpha), the ligand for the vertebrate EGFR (Massaque J, J Biol Chem.
(1990) 265:21393-21396). The rhomboid gene, which encodes a transmembrane protein,
30 is another upstream member of this pathway (Bier E., et al., Genes Dev. (1990) 4:190-
203). In *Drosophila*, rhomboid protein transforms Spitz from a membrane-bound to a
secreted form, and thus triggers and upregulates the DER signaling pathway (Wasserman
JD et al, Genes Devel (2000) 14:1651-1663). DNA sequences related to rhomboid have
been identified in *C. elegans* (Wasserman JD, and Freeman M, Trends Cell Biol (1997)

7:431-436), and in mammals Pascall JC, and Brown KD, FEBS letters (1998) 429:337-340; human: GI#3287191 and GI#7020534, among others; rat: GI#3297951), suggesting that rhomboid function may be evolutionarily conserved. Modulating signal transduction pathway activity involved in tumor growth and development is essential in understanding the development of many cancers, and eventually, for the treatment of cancer.

The ability to screen or manipulate the genomes of model organisms such as *Drosophila* provides a powerful means to analyze biochemical processes that, due to significant evolutionary conservation, have direct relevance to more complex vertebrate organisms. Due to high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between *Drosophila* and mammals, identification of novel genes involved in particular pathways and their functions in flies can directly contribute to the understanding of the correlative pathways and methods of modulating them in mammals (Mechler BM et al., 1985 EMBO J 4:1551-1557; Gateff E. 1982 Adv. Cancer Res. 37: 33-74; Watson KL., et al., 1994 J Cell Sci. 10: 18-33; Miklos GL, and Rubin GM. 1996 Cell 86:521-529; Wassarman DA, et al., 1995 Curr Opin Gen Dev 5: 44-50; Booth DR. 1999 Cancer Metastasis Rev. 18: 261-284). For example, a genetic screen can be carried out in *Drosophila* in which a gene of interest is overexpressed, resulting in a visible phenotype; a cross is made with flies having mutations in other genes; and progeny are identified that have an enhancement or reduction of the original overexpression phenotype, indicating that the mutated gene is a "modifier" involved in the same or overlapping pathway as the gene of interest (Rorth P., et al., Development (1998) 125:1049-1057; WO0015843). When the gene of interest is an ortholog of a human gene implicated in a disease pathway, such as a tumor suppressor gene or oncogene, modifier genes can be identified that may be attractive candidate targets 10 for novel therapeutics.

SUMMARY OF THE INVENTION

The present invention provides novel compound targets that are members of the Rhomboid class of proteins, hereinafter referred to as Rhomboid Related Proteins (RRP), and more specifically RRP1, RRP2, and RRP3, and are involved in the EGFR signaling pathway. The invention provides isolated nucleic acid molecules that comprise nucleic acid sequences encoding RRP protein as well as fragments and derivatives thereof. Vectors and host cells comprising the RRP nucleic acid molecules are also described.

The invention provides transgenic, nonhuman mammals containing a transgene encoding a RRP polypeptide or a gene effecting the expression of a RRP polypeptide. Such transgenic nonhuman mammals are particularly useful as *in vivo* test systems for studying the effects of introducing a RRP polypeptide, and regulating the expression of a RRP polypeptide (e.g., through the introduction of additional genes, antisense nucleic acids, etc).

5 The present invention further provides methods of modulating the interaction of RRP proteins with their pathway members. The present invention also provides methods of specifically inhibiting growth of tumor cells that overexpress RRP gene products. The
10 invention provides methods of screening for agents that modulate the interaction of an RRP polypeptide with an RRP binding target.

15 Modulating agents identified using the methods can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein. Preferred modulating agents include RRP-specific antibodies and small molecules identified in high throughput screens.

DETAILED DESCRIPTION OF THE INVENTION

An overexpression screen was carried out in *Drosophila* to identify genes that interact with the cyclin dependent kinase inhibitor, p21 (Bourne HR, et al., Nature (1990) 20 348(6297):125-132; Marshall CJ, Trends Genet (1991) 7(3):91-95). *Drosophila* Rhomboid was identified as a modifier of the p21 pathway. Accordingly, vertebrate orthologs of *Drosophila* Rhomboid, preferably human orthologs, hereinafter referred to as Rhomboid Related Proteins (RRP), and in more specific embodiments, RRP1, RRP2, and RRP3, are attractive drug targets for the treatment of pathologies associated with a defective p21 signaling pathway, such as cancer.

25 Rhomboid Related Proteins (RRPs) are a family of integral membrane proteins that contain five or more transmembrane domains and three strongly conserved histidine residues in the putative transmembrane regions. Rhomboid domains of RRP can be identified using the PFAM program (PFAM 01694; Bateman A., et al., Nucleic Acids Res, 30 1999, 27:260-2; <http://pfam.wustl.edu>). Sequences related to RRP DNA (RRP1: SEQ ID NO:1, RRP2: SEQ ID NO:3, and RRP3: SEQ ID NO:5) and protein (RRP1: SEQ ID NO:2, and RRP2: SEQ ID NO:4) are available in the public databases (for RRP1: cDNA: GI#3287190; proteins GI#3287191; for RRP2: cDNAs: Unigene Hs1969735, GI#s: 12762689, 12096415, 6657080, 7947756, 3117010, 9339870, 7152496, 11317512,

11317513, and 11317511 proteins: GI#s:8923409, 12719522, and 11421817; for RRP3: cDNA: GI#10199673 and GI#2003992). RRP DNA sequences encode transmembrane proteins. The extracellular or intracellular domains of RRP1 protein (SEQ ID NO:2) are located approximately at amino acid residues 1-195, 217-265, 281-283, 305-307, 329-372, 5 393-403, and 424- 438. The extracellular or intracellular domains of RRP2 protein (SEQ ID NO:4) are located approximately at amino acid residues 1-70, 92-132, 154-158, 180-182, 204-207, 229-247, 269-277, and 299-303. The extracellular or intracellular domains of RRP3 protein (SEQ ID NO:6) are located approximately at amino acid residues 1-117, 139-183, 205-207, 229-231, 253-296, 318-325, and 347-362. PFAM database (Bateman 10 A et al, supra) search results for RRP locate their rhomboid domains approximately at amino acid residues 239-396 for RRP1, 114-269 for RRP2, and 163-320 for RRP3.

The method of this invention is useful in the therapy of malignant or benign tumors of mammals that overexpress RRP gene products. Results from SAGE (serial analysis of gene expression) indicate overexpression of human RRP1 genes in cancers of the brain, 15 breast, and colon; overexpression of human RRP2 gene in cancers of the pancreas and mesothelium (linings of the abdominal and pleural cavity); and overexpression of human RRP3 genes in cancers of the brain and prostate.

Northern Blot analysis of mRNA from tumor samples, using full or partial RRP1 (SEQ ID NO:1), RRP2 (SEQ ID NO:3), and RRP3 (SEQ ID NO:5) cDNA sequences as 20 probes, can determine whether particular tumors overexpress RRP (Current Protocol in Molecular Biology, Eds. Asubel, et al., Wiley interscience, NY). Alternatively, the TaqMan® is used for analysis of RRP expression in tumor samples (PE Applied Biosystems).

25 Nucleic acids of the invention

A first aspect of the invention is a nucleic acid which encodes a human RRP3 as shown as SEQ ID NO:5. The DNA and RNA sequences of the invention can be single- or double-stranded. Thus, the term “isolated nucleic acid sequence”, as used herein, includes the reverse complement, RNA equivalent, DNA or RNA single- or double-stranded 30 sequences, and DNA/RNA hybrids of the sequence being described, unless otherwise indicated.

A part of the first aspect of the invention includes a fragment of a nucleic acid, such as a fragment that encodes a binding domain of one of the full-length sequences of the invention. Fragments of the RRP3 nucleic acid sequences can be used for a variety of

purposes. As an example, interfering RNA (RNAi) fragments, particularly double-stranded (ds) RNAi, can be used to generate loss-of-function phenotypes, which can, in turn, be used, among other uses, to determine gene function. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and humans are known in the art (Fire A, et al., Nature 391:806-811 (1998); Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S. M., et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239-245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, S. M., et al., Nature 404, 293-296 (2000); Zamore, P. D., et al., Cell 101, 25-33 (2000); Bernstein, E., et al., Nature 409, 363-366 (2001); Elbashir, S. M., et al., Genes Dev. 15, 188-200 (2001); WO0129058; WO9932619; Elbashir SM, et al., 2001 Nature 411:494-498).

Certain "antisense" fragments, i.e. that are reverse complements of portions of the coding and/or untranslated regions (e.g. 5' UTR) of SEQ ID NO:5 have utility in inhibiting the function of RRP3 proteins. The fragments are of length sufficient to specifically hybridize with the corresponding SEQ ID NO:5. The fragments consist of or comprise at least 12, preferably at least 24, more preferably at least 36, and more preferably at least 96 contiguous nucleotides of SEQ ID NO:5. When the fragments are flanked by other nucleic acid sequences, the total length of the combined nucleic acid sequence is less than 15 kb, preferably less than 10 kb or less than 5kb, more preferably less than 2 kb, and in some cases, preferably less than 500 bases.

Additional preferred fragments of SEQ ID NO:5 encode extracellular or intracellular domains which are located at approximately nucleotides 248-598, 665-796, 862-870, 934-943, 1006-1138, 1201-1225, and 1289-1336. Preferred fragments may also include a binding domain or an RRP motif (e.g. PFAM 01694). These domains may be useful to locate the function and/or binding partners of a protein. For example, a nucleic acid that encodes an extracellular or intracellular domain of a protein may be used to screen for binding partners related to the protein.

The subject nucleic acid sequences may consist solely of SEQ ID NO:5 or fragments thereof. Alternatively, the subject nucleic acid sequences and fragments thereof may be joined to other components such as labels, peptides, agents that facilitate transport across cell membranes, hybridization-triggered cleavage agents or intercalating agents. The subject nucleic acid sequences and fragments thereof may also be joined to other nucleic acid sequences (i.e. they may comprise part of larger sequences) and are of synthetic/non-natural sequences and/or are isolated and/or are purified, i.e. unaccompanied

by at least some of the material with which it is associated in its natural state. Preferably, the isolated nucleic acids constitute at least about 0.5%, and more preferably at least about 5% by weight of the total nucleic acid present in a given fraction, and are preferably recombinant, meaning that they comprise a non-natural sequence or a natural sequence joined to nucleotide(s) other than that which it is joined to on a natural chromosome.

Derivative nucleic acid sequences of RRP3 include sequences that hybridize to the nucleic acid sequence of SEQ ID NO:5. Various hybridization conditions are well-known to those skilled in the art (*Current Protocol in Molecular Biology, supra*). Specifically, stringent hybridization conditions may be employed: buffer comprising 30% formamide in 5 x SSPE (0.18 M NaCl, 0.01 M NaPO₄, pH7.7, 0.001 M EDTA) buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE; preferably hybridizing in a buffer comprising 50% formamide in 5 x SSPE buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE buffer at 42°C.

The subject nucleic acids find a wide variety of applications including use as translatable transcripts, hybridization probes, PCR primers, diagnostic nucleic acids, etc.; use in detecting the presence of RRP3 genes and gene transcripts and in detecting or amplifying nucleic acids encoding additional RRP3 homologs and structural analogs. In diagnosis, RRP3 hybridization probes find use in identifying wild-type and mutant RRP3 alleles in clinical and laboratory samples. Mutant alleles are used to generate allele-specific oligonucleotide (ASO) probes for high-throughput clinical diagnoses. In therapy, therapeutic RRP3 nucleic acids are used to modulate cellular expression or intracellular concentration or availability of active RRP3.

As used herein, "percent (%) nucleic acid sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides in the candidate derivative nucleic acid sequence identical with the nucleotides in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul *et al.*, J. Mol. Biol. (1997) 215:403-410; <http://blast.wustl.edu/blast/README.html>; hereinafter referred to generally as "BLAST") with all the search parameters set to default values. Derivative RRP3 nucleic acid sequences usually have at least 70% sequence identity, preferably at least 80% sequence identity, more preferably at least 85% sequence identity, still more

preferably at least 90% sequence identity, and most preferably at least 95% sequence identity with SEQ ID NO:5, or domain-encoding regions thereof.

In one preferred embodiment, the derivative nucleic acid encodes a polypeptide comprising a RRP3 amino acid sequence of SEQ ID NO:6, or a fragment or derivative thereof. A derivative RRP3 nucleic acid sequence, or fragment thereof, may comprise 100% sequence identity with SEQ ID NO:5, but be a derivative thereof in the sense that it has one or more modifications at the base or sugar moiety, or phosphate backbone. Examples of modifications are well known in the art (Bailey, Ullmann's Encyclopedia of Industrial Chemistry (1998), 6th ed. Wiley and Sons). Such derivatives may be used to provide modified stability or any other desired property.

More specific embodiments of preferred RRP3 protein fragments and derivatives are discussed below in connection with specific RRP3 proteins.

Proteins of the invention

As a second aspect, the invention is drawn to RRP proteins of which comprise or consist of an amino acid sequence of SEQ ID NOs:4 or 6, or fragments or derivatives thereof. Compositions comprising these proteins may consist essentially of the RRP protein, fragments, or derivatives, or may comprise additional components (*e.g.* pharmaceutically acceptable carriers or excipients, culture media, *etc.*).

RRP protein derivatives typically share a certain degree of sequence identity or sequence similarity with SEQ ID NOs:4 or 6, or a fragment thereof. As used herein, "percent (%) amino acid sequence identity" with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of amino acids in the candidate derivative amino acid sequence identical with the amino acid in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by BLAST (Altschul *et al.*, *supra*) using the same parameters discussed above for derivative nucleic acid sequences. A % amino acid sequence identity value is determined by the number of matching identical amino acids divided by the sequence length for which the percent identity is being reported. "Percent (%) amino acid sequence similarity" is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation. A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or

activity of the protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids 5 are arginine, lysine and histidine; interchangeable acidic amino acids aspartic acid and glutamic acid; and interchangeable small amino acids alanine, serine, cysteine, threonine, and glycine.

In one preferred embodiment, an RRP protein derivative shares at least 80% sequence identity or similarity, preferably at least 85%, more preferably at least 90%, and 10 most preferably at least 95% sequence identity or similarity with a contiguous stretch of at least 25 amino acids, preferably at least 50 amino acids, more preferably at least 100 amino acids, and in some cases, the entire length of SEQ ID NOs:4 or 6. In a preferred embodiment, the identity is shared with the RRP domain (PFAM 01694).

The fragment or derivative of the RRP protein is preferably "functionally active" 15 meaning that the RRP protein derivative or fragment exhibits one or more functional activities associated with a full-length, wild-type RRP protein comprising the amino acid sequence of SEQ ID NOs:4 or 6. Preferably, a functionally active RRP fragment or derivative is one that displays one or more biological activities associated with RRP proteins. As one example, a fragment or derivative may have antigenicity such that it can 20 be used in immunoassays, for immunization, for modulation of RRP activity, *etc*, as discussed further below regarding generation of antibodies to RRP proteins. For purposes herein, functionally active fragments also include those fragments that exhibit one or more structural features of an RRP, such as extracellular or intracellular domains. The functional activity of RRP proteins, derivatives and fragments can be assayed by various 25 methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan *et al.*, eds., John Wiley & Sons, Inc., Somerset, New Jersey).

RRP derivatives can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, a cloned RRP gene sequence can be cleaved at appropriate sites with restriction 30 endonuclease(s) (Wells *et al.*, Philos. Trans. R. Soc. London SerA (1986) 317:415), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*, and expressed to produce the desired derivative. Alternatively, an RRP gene can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or to form new restriction

endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. A variety of mutagenesis techniques are known in the art such as chemical mutagenesis, *in vitro* site-directed mutagenesis (Carter *et al.*, Nucl. Acids Res. (1986) 13:4331), use of TAB[®] linkers (available from Pharmacia and Upjohn, Kalamazoo, MI), *etc.*

5 At the protein level, manipulations include post translational modification, *e.g.* glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, *etc.* Any of numerous chemical modifications may be carried out by known technique (*e.g.* specific chemical cleavage by cyanogen bromide, trypsin,

10 chymotrypsin, papain, V8 protease, NaBH₄, acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin, *etc.*). Derivative proteins can also be chemically synthesized by use of a peptide synthesizer, for example to introduce nonclassical amino acids or chemical amino acid analogs as substitutions or additions into the RRP protein sequence.

15 Chimeric or fusion proteins can be made comprising an RRP protein or fragment thereof (preferably comprising one or more structural or functional domains of the RRP protein) joined at its amino- or carboxy-terminus via a peptide bond to an amino acid sequence of a different protein. Chimeric proteins can be produced by any known method, including: recombinant expression of a nucleic acid encoding the protein (comprising a

20 RRP-coding sequence joined in-frame to a coding sequence for a different protein); ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other in the proper coding frame, and expressing the chimeric product; and protein synthetic techniques, *e.g.* by use of a peptide synthesizer.

The subject RRP polypeptides also encompass minor deletion mutants, including
25 N-, and/or C-terminal truncations. Such deletion mutants are readily screened for RRP competitive or dominant negative activity.

RRP expression and production

RRP polypeptides may be purified from cells that normally synthesize them,
30 produced by recombinant technology from cultured cells, or synthesized in cell-free systems (*e.g.* Jermutus L, *et al.*, Curr Opin Biotechnol. (1998) 9:534-48). A wide variety of molecular and biochemical methods are available for biochemical synthesis, molecular expression and purification of the subject compositions (Sambrook *et al.*, Molecular Cloning, Cold Spring Harbor (1989), Current Protocols in Molecular Biology (*supra*)).

Synthesized or recombinant produced polypeptides are generated from polynucleotides that encode them. These may be naturally-encoding polynucleotides isolated with degenerate oligonucleotide primers and probes generated from the subject polypeptide sequences ("GCG" software, Genetics Computer Group, Inc, Madison WI), or 5 polynucleotides optimized for selected expression systems made by back-translating the subject polypeptides according to computer algorithms (e.g. Holler et al., Gene (1993) 136: 323-328; Martin et al., Gene (1995) 154:150-166). In one embodiment, recombinant cells that express RRP under the control of a heterologous promoter are used in assays to screen for agents that modulate RRP function, as described further below.

10

RRP-modulating agents

The invention provides methods of identifying and making such modulating agents, and their use in diagnosis, therapy and pharmaceutical development. Chemical binding agents can be identified by screening of chemical libraries such as *in vitro*, cell-based and animal-based binding assays described further below, or otherwise known to those of skill in the art. Endogenous RRP-specific binding agents and other natural intracellular binding agents can be identified using one-, two- and three-hybrid screens. RRP-binding specificity may be assayed by TGF α processing (e.g. ability of the candidate RRP-specific binding agents to function as negative effectors in RRP-expressing cells), by 15 binding equilibrium constants (usually at least about 10^7 M^{-1} , preferably at least about 10^8 M^{-1} , more preferably at least about 10^9 M^{-1}), by immunogenicity (e.g. ability to elicit RRP 20 specific antibody in a heterologous host such as a mouse, rat, goat or rabbit), etc.

The invention also provides RRP-modulating agents that act by inhibiting or enhancing RRP expression or directly or indirectly affect RRP binding activity. RRP-modulating agents include RRP mutant proteins (e.g. dominant negative mutants), RRP-specific antibodies, and chemical agents that specifically bind RRP. Preferred RRP-modulating agents specifically bind to RRP polypeptides and inhibit RRP function. RRP-specific binding agents may be evaluated by any convenient *in vitro* or *in vivo* assay for its molecular interaction with an RRP polypeptide. Preferably, the RRP polypeptide is from a 25 human source (e.g. SEQ ID NOs:2, 4, or 6), but can be a homolog or ortholog thereof (e.g. with at least 80%, preferably 85%, more preferably 90%, and most preferably at least 30% 30 sequence identity with SEQ ID NOs:2, 4, or 6). The binding agent may be endogenous, i.e. one normally implicated in RRP signal transduction such as TGF α , EGF, amphiregulin, heregulin, an RRP regulating protein, or another pathway regulator that

directly modulates RRP activity or its localization. Alternatively, the binding agent may be exogenous, such as RRP-specific antibodies, T-cell antigen receptors (see, e.g Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory) or a chemical binding agent, such as a chemical agent identified by an assay of the present
5 invention.

Specific binding agents such as antibodies and RRP-specific small molecules, as discussed further below, are useful in a variety of diagnostic and therapeutic applications, especially where disease or disease prognosis is associated with a pathway that involves RRP such as the EGFR pathway. Accordingly, the invention also provides methods for
10 modulating the EGFR pathway in a cell comprising the step of modulating RRP activity.

RRP Specific Antibodies

Antibodies that specifically bind RRP proteins can be generated. The antibodies have therapeutic and diagnostic utilities, and uses in functional validation of RRP genes
15 and proteins. For example, uses for antibodies include the detection of an RRP protein in a biological sample and the inhibition of RRP activity, for instance, to block the development of an oncogenic disorder. The antibodies can also be used in dissecting the portions of the RRP pathway responsible for various cellular responses and in the general processing and maturation of the RRP.

20 Antibodies that specifically bind RRP polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian RRP protein, and more preferably, a human RRP protein. Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab').sub.2 fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id)
25 antibodies, and epitope-binding fragments of any of the above. Antibodies may be generated against crude cell extracts of RRP or substantially purified fragments thereof. If RRP fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of an intracellular or extracellular domain of RRP.

30 Polyclonal antibodies to the various RRP polypeptide and peptide fragments may be prepared. In a particular embodiment, the subject polypeptides provide RRP-specific antigens and/or immunogens that are coupled to carrier proteins, which stimulate their own immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system

such as laboratory rabbits or mice are immunized according to conventional protocols and bled to recover the antibodies. The presence of RRP-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding RRP polypeptides. Other assays, such as
5 radioimmunoassays or fluorescent assays might also be used.

Monoclonal antibodies (mAbs) are homogenous, clonally derived, and bind with single antigenic determinants. When monoclonal antibodies (mAbs) are generated, they preferably have affinities of at least 10^8 M^{-1} , and preferably 10^9 M^{-1} to 10^{10} M^{-1} , or stronger. Standard procedures for mAbs are known in the art (Harlow and Lane,
10 Antibodies: A Laboratory Manual, CSH Laboratory (1988); Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292, 4,451,570 and 4,618,577). Briefly, appropriate animals will be selected and the desired immunization protocol followed. After the appropriate period of time, the spleens of such animals are excised and individual spleen cells fused, typically, to
15 immortalized myeloma cells under appropriate selection conditions. The cells are then clonally separated, and the supernatants of all clones tested by ELISA for their production of an antibody specific for the desired region of the antigen.

Chimeric antibodies specific to RRP polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin
20 constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608;
25 Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized
30 antibodies contain ~10% murine sequences and ~90% human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in

the art (U.S. Pat. No. 5,530,762; U.S. Pat. No. 5,585,089; U.S. Pat. No. 5,603,762, and U.S. Pat. No. 6,180,370).

RRP-specific single chain antibodies, which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via 5 an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).

Other suitable techniques for antibody production involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of 10 antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281).

The antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134).

15 A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 20 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be produced (U.S. Pat. No. 4,816,567).

Therapeutic Uses of the Antibodies

When used for anti-tumor therapy in a patient, the antibodies of the subject 25 invention are administered to the patient in therapeutically effective amounts that eliminate or reduce the patient's tumor burden. They will normally be administered parenterally, when possible at the target cell site, or intravenously. The dose and dosage regimen will depend upon the nature of the cancer (primary or metastatic), its population, the target site, the characteristics of the particular immunotoxin (when used), e.g., its 30 therapeutic index, and the patient's history. The amount of antibody administered will typically be in the range of approximately 0.1 - 10 mg/kg of patient weight. Treatment regimens using therapeutic antibodies are known in the art (e.g. U.S. Pat. No. 5,859,206).

As is known in the art, the selection of an appropriate antibody subclass for therapy will depend upon the nature of the tumor antigen. For example, an IgM may be

preferred when the antigen is highly specific for the tumor target and rarely occurs on normal cells. However, the IgG subclass may be preferred when the tumor-associated antigen is also expressed in normal tissues, even at much lower levels. The binding of at least two IgG molecules in close proximity is required to activate complement, a serum protein that combines with antibodies to form a defense against cellular antigens. The normal tissues that express smaller amounts of the antigen and bind fewer IgG molecules may thus incur less complement-mediated damage. Furthermore, since IgGs are smaller than IgMs, they may more readily localize to tumor tissue.

Immune responses may assist in the delivery or efficacy of an anti-tumor treatment. There is evidence that complement activation leads to an inflammatory response and macrophage activation (Uananue and Benecerraf, *Textbook of Immunology*, 2nd Edition, Williams & Wilkins, p. 218 (1984)). Activated macrophages more preferentially destroy tumor cells than normal cells (Fidler and Poste, *Springer Semin. Immunopathol.* 5, 161 (1982)). Also, the increased vasodilation accompanying inflammation may increase the ability of anti-cancer agents, such as chemotherapeutic drugs or radiolabeled antibodies to localize in tumors. While a significant detriment of standard chemotherapy or radiation treatment is damage to healthy cells, the antigen-antibody combinations specified by this invention may circumvent many of the problems normally caused by the heterogeneity of tumor cell populations. Additionally, purified antigens (Hakomori, *Ann. Rev. Immunol.* (1984) 2:103) or the related anti-idiotypic antibodies (Nepom et al., *Proc. Natl. Acad. Sci.* (1985) 81:2864; Koprowski et al., *Proc. Natl. Acad. Sci.* (1984) 81:216) which recognize the hypervariance among the same epitopes in different individuals could be used to induce an active immune response in human cancer patients. Such a response includes the formation of antibodies capable of activating human complement and mediating antibody-dependent cell-mediated cytotoxicity and by such mechanisms cause tumor destruction.

Non-antibody modulators of RRP function

The invention provides efficient methods of identifying non-antibody modulators of RRP function, and preferably chemical agents, e.g. lead compounds that can modulate RRP by gene expression, transcription, or cellular function. A wide variety of assays for transcriptional modulators or binding agents can be used, including labeled *in vitro* ligand binding assays, immunoassays, etc. (Harlow and Lane, *Antibodies, supra*; Knopfel et al., *J. Med. Chem.* (1995) 38:1417). The methods are amenable to automated, cost-effective

high throughput screening of chemical libraries for lead compounds. Identified reagents can be used in the pharmaceutical industries for animal and human trials. Assays for binding agents include screens for compounds that modulate RRP interaction with a natural RRP binding target. The RRP polypeptide used in such assays may be fused to another polypeptide such as a peptide tag for detection or anchoring, etc. In a particular embodiment, the binding target is TGF α , or a portion thereof, which provides binding affinity and avidity to the subject RRP polypeptide conveniently measurable in the assay and preferably comparable to the intact TGF α . Candidate binding agents encompass numerous chemical classes. They are typically organic compounds, preferably small (e.g., 5 preferably having a molecular weight of less than 10,000, more preferably less than 5,000, still most preferably less than 1,000, and most preferably less than 500), and are obtained from a wide variety of sources including libraries of synthetic or natural compounds. A 10 variety of other reagents may also be included in the mixture such as salts, buffers, neutral proteins such as albumin, detergents, protease inhibitors, nuclease inhibitors, antimicrobial 15 agents, etc. The resultant mixture is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the RRP polypeptide specifically binds the cellular binding target, portion or analog with a reference binding affinity. The mixture components can be added in any order that allow the requisite bindings, and incubations may be performed at any temperature that facilitates binding. Incubation 20 periods are likewise selected for optimal binding but also minimized to facilitate rapid, high-throughput screening.

After incubation, any agent-biased binding between the RRP polypeptide and one or more binding targets is detected by any of a variety of methods depending on the nature of the product and other assay components, such as through optical or electron density, 25 radiative emissions, nonradiative energy transfers, etc. or indirect detection with antibody conjugates, etc. A difference in the binding affinity of RRP to the target in the absence of the agent, as compared with the binding affinity in the presence of the agent indicates that the agent modulates the binding of the RRP to the RRP binding target, i.e. there is "agent-biased" binding. A difference, as used herein, is statistically significant and preferably 30 represents at least a 50%, preferably at least 60%, more preferably 75%, and most preferably a 90% difference.

Compound Formulations

The compounds identified in the assays of the invention described herein are typically formulated in pharmaceutical compositions, for example, as composition that comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipient(s). Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition.

Genetically modified animals

A preferred method of secondary validation of modulating agents is the use of animals and/or animal models, such as models of EGFR-related pathologies. Accordingly, the invention provides non-human animals that have been genetically modified to alter RRP expression. Preferably, the altered RRP expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control non-human animals having normal RRP expression. The genetically modified animal may additionally have altered EGFR expression. Preferred genetically modified animals are mammals such as primates, rodents (preferably mice), cows, horses, goats, sheep, pigs, dogs and cats. Preferred non-mammalian species include Zebrafish, *C. elegans*, and *Drosophila*. Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4:761-763.) or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.

Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster et al., Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al., U.S. Pat. No. 4,873,191 by Wagner et al., U.S. Pat. No. 6,127,598, by German et al., and Hogan, B., Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sandford et al.; for transgenic *Drosophila* see Rubin and Spradling, Science (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. et al., A Universal Marker for Transgenic Insects (1999) Nature 402:370-371; for transgenic Zebrafish see Lin S.,

Transgenic Zebrafish, *Metab Mol Biol.* (2000);136:375-3830); for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, *Experientia* (1991) 47:897-905; for transgenic rats see Hammer *et al.*, *Cell* (1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection see, for example, *Teratocarcinomas and Embryonic Stem Cells, A Practical Approach*, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. *et al.* (1997) *Nature* 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669).

In one embodiment, the transgenic animal is a "knock-out" animal having a heterozygous or homozygous alteration in the sequence of an endogenous RRP gene that results in a decrease of RRP function, preferably such that RRP expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse RRP gene is used to construct a homologous recombination vector suitable for altering an endogenous RRP gene in the mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, *Science* (1989) 244:1288-1292; Joyner *et al.*, *Nature* (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, *supra*; Pursel *et al.*, *Science* (1989) 244:1281-1288; Simms *et al.*, *Bio/Technology* (1988) 6:179-183).

In another embodiment, the transgenic animal is a "knock-in" animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the RRP gene, e.g., by introduction of additional copies of RRP, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the RRP gene. Such regulatory sequences include inducible, tissue-specific, and constitutive promoters and enhancer elements. The knock-in can be homozygous or heterozygous.

Transgenic nonhumans animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system is the

cre/loxP recombinase system of bacteriophage P1 (Lakso *et al.*, PNAS (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through
5 the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.* (1991) Science 251:1351-1355; U.S. Pat. No. 5,654,182).

10 The genetically modified animals can be used in genetic studies to further elucidate the EGFR pathway, as animal models of disease and disorders implicating defective EGFR pathway function, and for *in vivo* testing of candidate therapeutic agents, such as those identified in the above-identified screens. The candidate therapeutic agents are administered to a genetically modified animal having altered RRP function and phenotypic
15 changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered RRP expression that receive candidate therapeutic agent.

Gene Therapy

20 RRP sequences of the invention will also be useful in gene therapy (reviewed in Miller, Nature 357:455-460, 1992; Badiavas EV and Falanga V., J. Dermatol (2001) Apr;28(4):175-92; Maron *et al.* Surg Oncol Clin N Am (2001) Apr;10(2):449-60; and Mulligan, Science 260:926-931 (1993)). Recent advances in gene therapy have resulted in positive results.

25 In one preferred embodiment, an expression vector containing a RRP coding sequence, such as a dominant negative form, is inserted into cells. The cells are grown *in vitro* and then infused into patients. In another preferred embodiment, a DNA segment containing a heterologous promoter or enhancer is transferred into cells containing an endogenous gene encoding RRP of the invention in such a manner that the
30 promoter/enhancer segment enhances expression of the endogenous RRP gene (for example, the promoter segment is transferred to the cell such that it becomes directly linked to the endogenous RRP gene).

The gene therapy methods involve the use of an adenovirus containing RRP cDNA targeted to a tumor, systemic RRP increase by implantation of engineered cells, injection with RRP encoding virus, or injection of naked RRP DNA into appropriate tissues.

Target cell populations may be modified by introducing altered forms of one or 5 more components of the protein complexes in order to modulate the activity of such complexes. For example, by reducing or inhibiting a complex component activity within target cells, an abnormal signal transduction event(s) leading to a condition may be decreased, inhibited, or reversed. Deletion or missense mutants of a component, that retain the ability to interact with other components of the protein complexes but cannot 10 function in signal transduction, may be used to inhibit an abnormal, deleterious signal transduction event.

Expression vectors derived from viruses such as retroviruses, vaccinia virus, adenovirus, adeno-associated virus, herpes viruses, several RNA viruses, or bovine papilloma virus, may be used for delivery of nucleotide sequences (e.g., cDNA) encoding 15 recombinant RRP of the invention protein into the targeted cell population (e.g., tumor cells). Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors containing coding sequences (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1989; Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley 20 Interscience, N.Y., 1989). Alternatively, recombinant nucleic acid molecules encoding protein sequences can be used as naked DNA or in a reconstituted system e.g., liposomes or other lipid systems for delivery to target cells (e.g., Felgner et al., Nature 337:387-8, 1989). Several other methods for the direct transfer of plasmid DNA into 25 cells exist for use in human gene therapy and involve targeting the DNA to receptors on cells by complexing the plasmid DNA to proteins (Miller, *supra*).

In its simplest form, gene transfer can be performed by simply injecting minute amounts of DNA into the nucleus of a cell, through a process of microinjection (Capecci, Cell 22:479-88, 1980). Once recombinant genes are introduced into a cell, they can be recognized by the cell's normal mechanisms for transcription and translation, and a gene 30 product will be expressed. Other methods have also been attempted for introducing DNA into larger numbers of cells. These methods include: transfection, wherein DNA is precipitated with calcium phosphate and taken into cells by pinocytosis (Chen et al., Mol. Cell Biol. 7:2745-52, 1987); electroporation, wherein cells are exposed to large voltage pulses to introduce holes into the membrane (Chu et al., Nucleic Acids Res. 15:1311 -26,

1987); lipofection/liposomal fusion, wherein DNA is packaged into lipophilic vesicles which fuse with a target cell (Felgner et al., Proc. Natl. Acad. Sci. USA. 84:7413-7417, 1987); and particle bombardment using DNA bound to small projectiles (Yang et al., Proc. Natl. Acad. Sci. 87:9568-9572, 1990). Another method for introducing DNA into cells is 5 to couple the DNA to chemically modified proteins.

It has also been shown that adenovirus proteins are capable of destabilizing endosomes and enhancing the uptake of DNA into cells. The admixture of adenovirus to solutions containing DNA complexes, or the binding of DNA to polylysine covalently attached to adenovirus using protein crosslinking agents substantially improves the uptake 10 and expression of the recombinant gene (Curiel et al., Am. J. Respir. Cell. Mol. Biol., 6:247-52, 1992).

Gene transfer, the process of introducing a foreign nucleic acid molecule into a cell is commonly performed to enable the expression of a particular product encoded by the gene. The product may include a protein, polypeptide, antisense DNA or RNA, or 15 enzymatically active RNA. Gene transfer can be performed in cultured cells or by direct administration into animals. Generally gene transfer involves the process of nucleic acid contact with a target cell by non-specific or receptor mediated interactions, uptake of nucleic acid into the cell through the membrane or by endocytosis, and release of nucleic acid into the cyto-plasm from the plasma membrane or endosome. Expression may 20 require, in addition, movement of the nucleic acid into the nucleus of the cell and binding to appropriate nuclear factors for transcription. Gene transfer can be performed ex vivo on cells which are then transplanted into a patient, or can be performed by direct administration of the nucleic acid or nucleic acid-protein complex into the patient.

In another preferred embodiment, a vector having nucleic acid sequences encoding 25 a RRP polypeptide is provided in which the nucleic acid sequence is expressed only in specific tissue. Methods of achieving tissue-specific gene expression are set forth in International Publication No. WO 93/09236, filed November 3, 1992 and published May 13, 1993.

In all of the preceding vectors set forth above, a further aspect of the invention is 30 that the nucleic acid sequence contained in the vector may include additions, deletions or modifications to some or all of the sequence of the nucleic acid, as defined above.

In another preferred embodiment, a method of gene replacement, supplying a nucleic acid sequence which is capable of being expressed in vivo in an animal and

thereby providing or augmenting the function of an endogenous gene which is missing or defective in the animal is set forth.

The following experimental section and examples are offered by way of illustration and not by way of limitation.

5

EXAMPLES, PROTOCOLS AND EXPERIMENTAL PROCEDURES

I. High-Throughput In Vitro Fluorescence Polarization Assay

Fluorescently-labeled RRP peptide/TGF- α polypeptide are added to each well of a 96-well microtiter plate, along with a test compound of choice in a test buffer (10 mM 10 HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6). The amount of fluorescence polarization is then determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc).

II. Conformational Sensor - ELISA Format Assay

15 Various combinations of Glutathione-S-transferase/ TGF- α polypeptide fusion protein and biotinylated RRP are added to each well of a microtiter plate (Reacti-Bind Streptavidin-Coated, White Polystyrene Plates (#15118B), which have been blocked by Super-Blocking Reagent from Pierce) in assay buffer(0.01M HEPES, 0.15M NaCl, 0.002M MgCl₂). Test compounds are then added to each well, and incubated at room 20 temperature for 1 hour. Anti-GST, rabbit and anti-rabbit antibodies are then added to each well and incubated on ice for 1 hour. Plates are then washed with water, diluted Supersignal substrate is added to each well, and chemiluminescence is then measured.

III. High-Throughput In Vitro Binding Assay.

25 ³³P-labeled RRP peptide is added in an assay buffer (100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl₂, 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors) along with a compound of interest to the wells of a Neutralite-avidin coated assay plate, and incubated at 25°C for 1 hour. Biotinylated TGF- α polypeptide is then added to each well, and incubated for 1 hour. Reactions are stopped 30 by washing with PBS, and counted in a scintillation counter. Controls for the assays, located on each plate are non-biotinylated TGF- α polypeptide.

IV. Expression analysis

All cell lines used in the following experiments are NCI (National Cancer Institute) lines, and are available from ATCC (American Type Culture Collection, Manassas, VA 20110-2209). Normal and tumor tissues were obtained from Impath, UC Davis, Clontech, 5 Stratagene, and Ambion.

TaqMan® (PE Applied Biosystems) was used for analysis of human RRP1, RRP2, and RRP3 expression in normal human tissues, matched colon tumor and normal samples, pooled tumor tissues from breast, ovary, lung, prostate, and liver cancer, compared to normal and tumor cell lines. All procedures were carried out according to manufacturer's 10 protocols.

Normal human tissue samples. Ubiquitous expression of all rhomboids was observed in all tissues examined, with highest levels of expression in the brain. Higher expression in the spinal cord was also observed for RRP3.

Matched tumor and normal samples. Higher expression in colon tumor relative 15 to normal matched tissue was seen in 8 out of 18 tumors for RRP1, 1 out of 19 tumors for RRP2, and 4 out of 18 tumors for RRP3. In addition, RRP1 displayed higher expression in pooled tumor tissues from breast, ovarian, lung, prostate and liver cancer compared to normal. RRP2 was overexpressed in one pool of breast tumor and two pools of ovarian tissues compared to matched normal tissues. RRP3 expression was increased in one pool 20 of lung tumor tissue compared to matched normal tissue.

Tumor cell lines. Lymphoma, lung, breast, and colon tumor cell lines were used for these studies. RRP1 was expressed in all tumor lines, with highest expression levels in colon cancer; RRP2 showed increased expression only in breast cancer lines; and RRP3 expression was increased slightly in breast and colon cancer lines, but increased 25 significantly in lung cancer lines.

V. Cell Biology and Functional Characterization

RRP Localization. In Drosophila, rhomboid is a cell surface protein. However, localization of human RRP's has not happened to date. Furthermore, in humans, it is not 30 known whether each of the termini of the rhomboids is intracellular or extracellular. To answer these questions, RRP1 was subcloned into pcDNA expression vector (Invitrogen) in frame with myc-his tag at the c-terminus, according to manufacturer's protocols. The resulting expression vector was transiently transfected using Lipofectamine Plus reagent (Life technologies) into human embryonic kidney HEK-293 cells. Immunofluorescence

staining using anti-myc antibody was then carried out on the cells to localize RRP1. Results of these experiments indicated that RRP1 is expressed at the cell surface. Furthermore, permeabilized (0.1% triton in PBS) and non-permeabilized cells show the same staining pattern, indicating that the c-terminus of the protein is outside, and the N-terminus, inside. RRP2 and RRP3 are also subcloned and tagged at the c-terminus for localization of each protein, and also to assess the direction of the protein ends in each case.

10 **Involvement of RRP in EGFR signaling pathway.** While Drosophila rhomboid is essential in the EGFR pathway, the function of human RRPs have not been assessed to date. To assess the role of human RRPs in the EGFR signaling pathway, RRP1 was stably transfected using CaPO4 transfection kit (Clontech) into Hela cells, which have endogenous EGFR activity. Pooled stable cells were then examined in the following assays.

15 *EGFR activation as measured by tyrosine phosphorylation*

16 Hela cells overexpressing RRP1 and parental Hela cells were tested for EGFR tyrosine phosphorylation by immunoblot against anti-phosphotyrosine using anti-phosphotyrosine antibody (Upstate Biotechnology). Cells overexpressing RRP1 demonstrated up to two-fold increase in EGFR tyrosine phosphorylation as compared to parental Hela controls.

20 *EGFR expression in cells overexpressing RRP1.*

21 Expression of EGFR was increased when tested by immunoblot using anti-EGFR antibody against direct cell lysates in cells overexpressing RRP1. Furthermore, expression of EGFR was also increased in tumor samples overexpressing RRP1, by TaqMan® analysis. The correlation of both in-vitro and in-vivo results for concordant 25 overexpression of EGFR and RRP1 is quite significant, and provides a tool for assessing the functional relationship of the two proteins in any tumor sample or cell line.

Cell proliferation and Migration.

26 Hela cells overexpressing RRP1 demonstrate a two-fold increase in cell proliferation compared to Hela parental cells as measured by Procheck (Intergen) and 30 AlamarBlue (Biosource International) chemiluminescent assays. In addition, Fluroblock (BD Biosource) analysis showed a slight increase in motility in cells overexpressing RRP1 compared to Hela parental cells.

Taken together, these results demonstrate a strong functional conservation of rhomboids across evolution. Furthermore, increased RRP1 expression in tumor samples

and cell lines, concurrent increased expression of EGFR, and increased proliferation and motility of cells expressing RRP1 suggest involvement of RRP1 in various cancers. RRP1 expression levels can thus be used to screen for tumors with defective EGFR pathways, to identify tumors amenable to treatment with the compounds and antibodies identified by 5 the methods of the present invention. Same aforementioned experiments are performed with RRP2 and RRP3 to assess their involvement in the EGFR signaling pathway.

RRP1 binding target. In Drosophila, rhomboid transforms Spitz (homolog of human TGF- α) from a membrane-bound to a secreted form, and thus triggers and 10 upregulates the DER (Drosophila EGFR) pathway. No such function has been shown for human rhomboids. HEK293 cells were transiently co-transfected with RRP1 and TM-TGF- α (transmembrane-bound TGF), then immunoprecipitated with anti-myc antibody (for RRP1) and immunoblotted with anti-TGF- α . Cells transfected with vector alone, 15 RRP1 alone, or TM-TGF- α alone were used as controls. A band corresponding to the size of TGF- α was recognized by anti-TGF- α antibody, while no bands were detected in the control lanes. This data indicates that RRP1 physically interacts with TGF- α . The same experiments are performed with RRP2 and RRP3 to determine their binding partners.

Antibodies against human rhomboids. A peptide antibody, SEQ ID NO: 7 , and 20 referred to as peptide 1, was made against the N-terminus of RRP1. This antibody displayed strong affinity for denatured RRP1, such as in cells fixed with formalin or proteins on western blots. In addition, staining pattern remained the same when permeabilized cells were co-stained with anti-myc antibodies (for the c-terminus of RRP1) and peptide 1, suggesting that Peptide 1 does recognize RRP1. Furthermore, the cells 25 were significantly immunostained only when they were permeabilized, suggesting that the N-terminus of RRP1 is inside the cells. This result correlates with the previous staining pattern using anti-myc antibody for the C-terminus.

RRP1 protein expression in tumors was examined by Immunohistochemistry (IHC) using peptide 1. Positive staining on epithelial cells of colon adenocarcinoma tissue 30 sections were observed as compared to background staining in preimmune serum, suggesting the antibody is specific for its target, RRP1, in colon cancer cells. Moreover, increased staining of colorectal adenocarcinomas was observed compared to matched normal tissues using peptide 1 antibody. Taken together, these results suggest that peptide 1 antibody is a powerful tool to assess expression levels of RRP1 in tumor samples.

Antibodies are also produced against RRP2 and RRP3, to assess their expression levels in tumors.

One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned above, as well as those inherent therein. The molecular complexes and methods, procedures, treatments, molecules, specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. It will readily be apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

All patents and publications mentioned in the specification are indicative of the levels of skill to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

Other embodiments are within the following claims:

WHAT IS CLAIMED IS:

1. A method of specifically inhibiting growth of tumor cells that overexpress an RRP protein comprising contacting said tumor cells with an amount of an exogenous RRP binding agent that results in inhibition in growth of tumor cells.
5
2. The method of claim 1 wherein said tumor cells are from a tissue selected from the group consisting of brain, breast, ovary, lung prostate, liver, lymph nodes and colon.
3. The method of claim 1 wherein said RRP binding agent is an antibody or a fragment
10 of said antibody.
4. The method according to claim 2 wherein said antibody is humanized.
5. The method according to claim 2 wherein said antibody comprises human constant
15 region residues and rhomboid-specific mouse variable region residues.
6. The method according to claim 3 wherein said antibody is bound to a detectable label.
- 20 7. The method according to claim 3 wherein said antibody is bound to a cytotoxic label.
8. A method of screening for agents that modulate the interaction of an RRP polypeptide with an RRP binding target, comprising:
 - a) expressing a recombinant RRP polypeptide,
 - 25 b) incubating the recombinant RRP polypeptide with an RRP binding target and a candidate RRP modulating agent and
 - c) determining whether said candidate RRP modulating agent modulates the binding of the RRP polypeptide with the RRP binding target.
- 30 9. The method according to claim 8 wherein said binding target is selected from the group consisting of TGF α , EGF, and amphiregulin.
10. The method according to claim 8 wherein said binding target is TGF α .
- 35 11. The method according to claim 8 wherein said candidate RRP modulating agent is an antibody.
12. The method according to claim 8 wherein said candidate RRP modulating agent is a small organic molecule.

13. A method of diagnosing a tumor cell as having abnormal EGFR pathway signaling, comprising measuring RRP expression levels in said tumor cell, wherein increased RRP expression levels in the tumor cell compared to a non-tumor cell of the same tissue or organ as the tumor cell, indicates defective EGFR pathway signaling in the tumor cell.

5

14. An isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:4.

10 15. A recombinant expression system comprising a RRP2 polynucleotide, wherein said expression system is capable of producing a recombinant RRP2 polypeptide comprising the amino acid sequence of SEQ ID NO:4 when said expression system is present in a compatible host cell.

15 16. A host cell comprising the expression system of claim 15.

17. A process for producing a RRP2 protein comprising culturing the host cell of Claim 16 under conditions suitable for expression of said RRP2 protein and recovering said protein.

20

18. A process for producing a cell which produces a RRP2 protein comprising the transformation or transfection of a host cell with the expression system of claim 15 such that the host cell, under appropriate culture conditions, produces a RRP2 protein.

25 19. A recombinant host cell expressing the protein produced by the method of claim 18.

20. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:14.

30

21 A purified nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:6, or reverse complement thereof.

35

22. The nucleic acid molecule of Claim 21 which is capable of hybridizing to a nucleic acid sequence of SEQ ID NO:5 using hybridization conditions that comprise 6X SSC/0% formamide hybridization buffer at 25° C and 4X SSC wash buffer at 35° C.

23. The nucleic acid molecule of Claim 21 wherein said nucleic acid sequence encodes at least one RRP3 functional domain selected from the group consisting of [REDACTED] extracellular domain, an intracellular domain, and an RRP motif (PFAM 01694).

5 24. A recombinant expression system comprising a DNA or RNA molecule, wherein said expression system is capable of producing an RRP3 polypeptide comprising the amino acid sequence of SEQ ID NO:6 when said expression system is present in a compatible host cell.

10 25. A host cell comprising the expression system of claim 24.

26. A process for producing an RRP3 protein comprising culturing the host cell of Claim 25 under conditions suitable for expression of said RRP3 protein and recovering said protein.

15 27. A process for producing a cell which produces an RRP3 protein comprising the transformation or transfection of a host cell with the expression system of claim 24 such that the host cell, under appropriate culture conditions, produces an RRP3 protein.

20 28. A recombinant host cell expressing the protein produced by the method of claim 27.

SEQUENCE LISTING

<110> EXELIXIS, INC.

<120> HUMAN RRP SEQUENCES AND METHODS OF USE

<130> EX01-041C-PC

<150> 60/219,289

<151> 2000-07-19

<150> 60/277,487

<151> 2001-03-21

<150> 60/277,471

<151> 2001-03-21

<160> 7

<170> PatentIn version 3.0

<210> 1

<211> 1559

<212> DNA

<213> Homo sapiens

<400> 1

cttggacatt	ggccctcgct	ttccaggatg	ggtaggggtgg	aagacggggg	aacaactgag	60
gagctggagg	actgggaccc	aggcaccagt	gccctgccag	ctcctggat	caagcaggg	120
cccaggaaac	agacaggcac	ggggccccctg	tcccaaagt	gctggagcc	tgagcctgat	180
gctcccagcc	agcctggccc	agccctttgg	tccaggggtc	gggcccgcac	tcaggccttg	240
gctggcggt	cctcactgca	gcagctggac	cccgagaaca	caggcttcat	cggtgcggac	300
actttcaactg	gcctggtgca	cagccatgag	ctgccccctgg	acccggccaa	gctggacatg	360
ctggtgccccc	tggctcagag	caacgagcac	ggccaggtct	gctaccagga	gctggtgac	420
ctgatcagca	gcaagcgctc	cagcagtttc	aagcgggcca	ttgctaacgg	acagcgggca	480
ctgccccggg	acggggcgct	ggatgagcca	ggcctaggtg	tctacaagcg	gtttgtgcgt	540
tacgtggcct	acgagatct	gccttgtgag	gtggaccgccc	gctggtaactt	ctaccgtcac	600
cgcagctgcc	caccccccgt	gttcatggcc	tcggtcactc	ttgcccagat	catcgtgttc	660
ctgtgttacg	gggccccgcct	caacaagtgg	gtgctgcaga	cctaccaccc	cgagtacatg	720
aagagccccc	ttgtgtacca	ccccgggcac	cgtgcccgcg	cctggcgctt	cctcacctac	780
atgttcatgc	acgttgggct	ggagcagctg	gggttcaacg	ccctcctgca	gctgtatgatc	840
gggggtgcccc	tggagatgg	gcacggcctg	ctccgcacatca	gcctgctcta	cctggcaggc	900
gtgctggcag	gctccctaac	cgtctccatc	accgacatgc	gggccccgg	ggtgggaggc	960
tccggcgccc	tctacgcctt	gtgctggca	cacctggcca	acgttgtcat	gaactgggct	1020
gggatgagat	gtccctacaa	gttgctgagg	atggtgctgg	cttgggtgtg	catgagctcc	1080
gaggtgggccc	gggcccgtgt	gctgcgcctc	tccccgcgc	tgcccgctc	gggcccacag	1140
cccagcttca	tggcgcacct	ggcaggcgcg	gtggtgaaaa	tgagcatggg	cctgaccatc	1200
ctgcggagct	acgaggagcg	cctgcgggac	cagtgcggct	ggtgggtgg	gctgctggcc	1260
tacggcacct	tcctgcttt	cgccgtcttc	tggAACGTCT	tgcctacga	cctgctggcc	1320

gcccacatcc ccccaccgccc accggct acctgaggct gcacaggcca gggc[REDACTED]gc 1380
 atgtggtggc cgccccaccag gggccttcac gtctgccctt tgtgaacgga cgtctcaggg 1440
 ctgctgtgcc ccttgggtgt gggtggcctc aaaggaggcc ctgtcccagc cacccacccc 1500
 ccactcccag gacttgcggt ctgagccttt ttggataatt aataaatatt ttacacagc 1559

<210> 2
<211> 438
<212> PRT
<213> Homo sapiens
<400> 2

Met Gly Arg Val Glu Asp Gly Gly Thr Thr Glu Glu Leu Glu Asp Trp
 1 5 10 15
 Asp Pro Gly Thr Ser Ala Leu Pro Ala Pro Gly Ile Lys Gln Gly Pro
 20 25 30
 Arg Glu Gln Thr Gly Thr Gly Pro Leu Ser Gln Lys Cys Trp Glu Pro
 35 40 45
 Glu Pro Asp Ala Pro Ser Gln Pro Gly Pro Ala Leu Trp Ser Arg Gly
 50 55 60
 Arg Ala Arg Thr Gln Ala Leu Ala Gly Gly Ser Ser Leu Gln Gln Leu
 65 70 75 80
 Asp Pro Glu Asn Thr Gly Phe Ile Gly Ala Asp Thr Phe Thr Gly Leu
 85 90 95
 Val His Ser His Glu Leu Pro Leu Asp Pro Ala Lys Leu Asp Met Leu
 100 105 110
 Val Ala Leu Ala Gln Ser Asn Glu Gln Gly Gln Val Cys Tyr Gln Glu
 115 120 125
 Leu Val Asp Leu Ile Ser Ser Lys Arg Ser Ser Phe Lys Arg Ala
 130 135 140
 Ile Ala Asn Gly Gln Arg Ala Leu Pro Arg Asp Gly Pro Leu Asp Glu
 145 150 155 160
 Pro Gly Leu Gly Val Tyr Lys Arg Phe Val Arg Tyr Val Ala Tyr Glu
 165 170 175
 Ile Leu Pro Cys Glu Val Asp Arg Arg Trp Tyr Phe Tyr Arg His Arg
 180 185 190
 Ser Cys Pro Pro Pro Val Phe Met Ala Ser Val Thr Leu Ala Gln Ile
 195 200 205
 Ile Val Phe Leu Cys Tyr Gly Ala Arg Leu Asn Lys Trp Val Leu Gln
 210 215 220
 Thr Tyr His Pro Glu Tyr Met Lys Ser Pro Leu Val Tyr His Pro Gly
 225 230 235 240
 His Arg Ala Arg Ala Trp Arg Phe Leu Thr Tyr Met Phe Met His Val
 245 250 255
 Gly Leu Glu Gln Leu Gly Phe Asn Ala Leu Leu Gln Leu Met Ile Gly
 260 265 270
 Val Pro Leu Glu Met Val His Gly Leu Leu Arg Ile Ser Leu Leu Tyr
 275 280 285

Leu Ala Gly Val Leu Al~~y~~ 290 295 300
 Arg Ala Pro Val Val Gly 305 310 315 320
 Ala His Leu Ala Asn Val Val Met Asn Trp Ala Gly Met Arg Cys Pro
 325 330 335
 Tyr Lys Leu Leu Arg Met Val Leu Ala Leu Val Cys Met Ser Ser Glu
 340 345 350
 Val Gly Arg Ala Val Trp Leu Arg Phe Ser Pro Pro Leu Pro Ala Ser
 355 360 365
 Gly Pro Gln Pro Ser Phe Met Ala His Leu Ala Gly Ala Val Val Gly
 370 375 380
 Val Ser Met Gly Leu Thr Ile Leu Arg Ser Tyr Glu Glu Arg Leu Arg
 385 390 395 400
 Asp Gln Cys Gly Trp Trp Val Val Leu Leu Ala Tyr Gly Thr Phe Leu
 405 410 415
 Leu Phe Ala Val Phe Trp Asn Val Phe Ala Tyr Asp Leu Leu Gly Ala
 420 425 430
 His Ile Pro Pro Pro Pro
 435

<210> 3
 <211> 1224
 <212> DNA
 <213> Homo sapiens

<400> 3
 gggccat~~ttta~~ ggagg~~ttt~~tag atcatttga tcatcttcag ctgtcttc~~t~~ ttcacataca 60
 ggaaaggc~~c~~ tggaaagcag tcgttgc~~g~~cc agacagccc~~a~~ ggaaagagcg gcagc~~c~~t~~g~~ag 120
 gacctagg~~g~~ cacc~~t~~gctgt tccctggat tcatgtc~~c~~tt ctggggagga gggaggac~~c~~ 180
 aggacaatgg ctgctgttca tgatctggag atggagagca tgaatctgaa tatggggaga 240
 gagatgaaag aagagctgga ggaagaggag aaaatgagag aggatggggg aggtaaagat 300
 cgggccaaga gtaaaaaggt ccacaggatt gtctcaaaat g~~g~~atgctg~~c~~cc cgaaaagtcc 360
 cgaggaacat acttggagag agctaactgc ttcccgc~~t~~c ccgtgttcat catctccatc 420
 agcctggccg agctggc~~ag~~t gtttatttac tatgctgtgt ggaagcctca gaaacagtgg 480
 atcacgttgg acacaggcat cttggagagt cccttatct acagtcc~~t~~ga gaagagggag 540
 gaagcctgga ggttat~~c~~tc atacatgctg gtacatgctg gagttcagca catcttgggg 600
 aatcttgta tgcagcttgt tttgggtatt cc~~tt~~ggaaa tgg~~tt~~ccacaa agg~~c~~tc~~cc~~gt 660
 gtggggctgg tgtacctggc aggagtgatt gcagggtccc ttgccagctc catcttgc~~a~~c 720
 ccactcagat atcttgggg agcttcagga ggagtctatg ctctgatggg aggctatttt 780
 atgaatgttc tggtaattt tcaagaaatg at~~tc~~ctgc~~t~~c ttgaaat~~ttt~~ cagactgctg 840
 atcatcatcc tgataattgt gttggacatg ggatttgctc tctatagaag gttctttgtt 900
 cctgaagatg ggtctcc~~gg~~t gtctttgca gctcacattg caggtggatt tgctggaatg 960
 tccattggct acacggtg~~tt~~ tagctgcttt gataaagcac tgctgaaaga tccaagg~~t~~t 1020

tggatagcaa ttgctgcata	agcttgt gtcttattt ctgtgtttt caac	tc	1080
ctatccag caaactgacc tgcccattt gtaagtcaat taataaaaag agccatctgg			1140
aggaaataaa aaaaaaagga agactctatg aagaaacaga gaagtctcag aaaaggctaa			1200
caattttaga tagagaacaa aggg			1224

<210> 4
<211> 303
<212> PRT
<213> Homo sapiens

<400> 4

Met Ala Ala Val His Asp Leu Glu Met Glu Ser Met Asn Leu Asn Met
1 5 10 15

Gly Arg Glu Met Lys Glu Glu Leu Glu Glu Glu Lys Met Arg Glu
20 25 30

Asp Gly Gly Lys Asp Arg Ala Lys Ser Lys Lys Val His Arg Ile
35 40 45

Val Ser Lys Trp Met Leu Pro Glu Lys Ser Arg Gly Thr Tyr Leu Glu
50 55 60

Arg Ala Asn Cys Phe Pro Pro Pro Val Phe Ile Ile Ser Ile Ser Leu
65 70 75 80

Ala Glu Leu Ala Val Phe Ile Tyr Tyr Ala Val Trp Lys Pro Gln Lys
85 90 95

Gln Trp Ile Thr Leu Asp Thr Gly Ile Leu Glu Ser Pro Phe Ile Tyr
100 105 110

Ser Pro Glu Lys Arg Glu Glu Ala Trp Arg Phe Ile Ser Tyr Met Leu
115 120 125

Val His Ala Gly Val Gln His Ile Leu Gly Asn Leu Cys Met Gln Leu
130 135 140

Val Leu Gly Ile Pro Leu Glu Met Val His Lys Gly Leu Arg Val Gly
145 150 155 160

Leu Val Tyr Leu Ala Gly Val Ile Ala Gly Ser Leu Ala Ser Ser Ile
165 170 175

Phe Asp Pro Leu Arg Tyr Leu Val Gly Ala Ser Gly Gly Val Tyr Ala
180 185 190

Leu Met Gly Gly Tyr Phe Met Asn Val Leu Val Asn Phe Gln Glu Met
195 200 205

Ile Pro Ala Phe Gly Ile Phe Arg Leu Leu Ile Ile Leu Ile Ile
210 215 220

Val Leu Asp Met Gly Phe Ala Leu Tyr Arg Arg Phe Phe Val Pro Glu
225 230 235 240

Asp Gly Ser Pro Val Ser Phe Ala Ala His Ile Ala Gly Gly Phe Ala
245 250 255

Gly Met Ser Ile Gly Tyr Thr Val Phe Ser Cys Phe Asp Lys Ala Leu
260 265 270

Leu Lys Asp Pro Arg Phe Trp Ile Ala Ile Ala Ala Tyr Leu Ala Cys
275 280 285

Val Leu Phe Ala Val Phe Asn Ile Phe Leu Ser Pro Ala Asn
 290 295 300

<210> 5
 <211> 1376
 <212> DNA
 <213> Homo sapiens

<400> 5
 ctgaactgat gaggtttca tggaaatca gtgcctgtct gttcatctga acacccacta 60
 gttatttcattt caacaaatct tgatttagtg ctgataatgc caggctctgt gctaagtacc 120
 gggataagt tgtgataaccg acccgcgagg cgccgcggc caaggaggag gcaaaaagcag 180
 acagacatca gtgtggctg gaggcccaga ggtctggaca gaacagaggg ttccgtgaga 240
 acaggccatg gctgagttt accctggaa cacaggctac attagcacag gcaagttccg 300
 gagttttctg gagagccaca gctccaagct ggacccgcac aaaagggagg tcctcctggc 360
 tcttgcgcac agccacgcgg atgggcagat cggctaccag gattttgtca gcctagttag 420
 caacaagcgt tccaaacagct tccgccaagc catcctgcag ggcaaccgca ggctaagcag 480
 caaggccctg ctggaggaga aggggcttag cctctgcag cgacttatcc gccatgtggc 540
 ctatgagacc ctgccccggg aaattgaccg caagtggtag tatgacagct acacctgctg 600
 cccccccaccc tggttcatga tcacagtcac gctgctggag gttgccttt tcctctacaa 660
 tggggtgtca ctaggtcaat ttgtactgca ggtaactcat ccacgttact tgaagaactc 720
 cctggtttac cacccacagc tgcgagcaca ggtttggcgc tacctgacat acatttcat 780
 gcatgcaggg atagaacacc tggactcaa tgtggtgctg cagctgctgg tgggggtgcc 840
 cctggagatg gtgcatggag ccacccgaat tgggcttgctc tacgtggccg gtgttgtggc 900
 agggtccttg gcagtgctg tggctgacat gaccgctcca gtcgtggct cttctggagg 960
 ggtgtatgct ctcgtctctg cccatctggc caacattgtc atgaactggt caggcatgaa 1020
 gtgccagtcc aagctgtgc ggatggctgt ggccttatac tgtatgagca tggagtttg 1080
 gcggggccgtg tggctccgct tccacccgtc ggcctatccc ccgtgcctc acccaagctt 1140
 tgtggcgcac ttgggtggcg tggccgtggg catcaccctg ggcgtggtagg tcctgagggaa 1200
 ctacgagcag aggctccagg accagtcaact gtggtggtt tttgtggcca tgtacaccgt 1260
 cttcgtgctg ttcgctgtct tctgaaacat cttgcctac accctgctgg acttaaagct 1320
 gccgcctccc ccctgagggc tggaggccca aggtcgggga ggggagggaa aagcag 1376

<210> 6
 <211> 362
 <212> PRT
 <213> Homo sapiens

<400> 6

Met Ala Glu Phe Asp Pro Gly Asn Thr Gly Tyr Ile Ser Thr Gly Lys
 1 5 10 15

Phe Arg Ser Leu Leu Glu Ser His Ser Ser Lys Leu Asp Pro His Lys
 20 25 30

Arg Glu Val Leu Leu Ala Leu Ala Asp Ser His Ala Asp Gly Gln Ile
 35 40 45

Gly Tyr Gln Asp Phe Val Ser Leu Val Ser Asn Lys Arg Ser Asn Ser
 50 55 60

Phe Arg Gln Ala Ile Leu Gln Gly Asn Arg Arg Leu Ser Ser Lys Ala
 65 70 75 80

Leu Leu Glu Glu Lys Gly Leu Ser Leu Ser Gln Arg Leu Ile Arg His
 85 90 95

Val Ala Tyr Glu Thr Leu Pro Arg Glu Ile Asp Arg Lys Trp Tyr Tyr
 100 105 110

Asp Ser Tyr Thr Cys Cys Pro Pro Trp Phe Met Ile Thr Val Thr
 115 120 125

Leu Leu Glu Val Ala Phe Phe Leu Tyr Asn Gly Val Ser Leu Gly Gln
 130 135 140

Phe Val Leu Gln Val Thr His Pro Arg Tyr Leu Lys Asn Ser Leu Val
 145 150 155 160

Tyr His Pro Gln Leu Arg Ala Gln Val Trp Arg Tyr Leu Thr Tyr Ile
 165 170 175

Phe Met His Ala Gly Ile Glu His Leu Gly Leu Asn Val Val Leu Gln
 180 185 190

Leu Leu Val Gly Val Pro Leu Glu Met Val His Gly Ala Thr Arg Ile
 195 200 205

Gly Leu Val Tyr Val Ala Gly Val Val Ala Gly Ser Leu Ala Val Ser
 210 215 220

Val Ala Asp Met Thr Ala Pro Val Val Gly Ser Ser Gly Gly Val Tyr
 225 230 235 240

Ala Leu Val Ser Ala His Leu Ala Asn Ile Val Met Asn Trp Ser Gly
 245 250 255

Met Lys Cys Gln Phe Lys Leu Leu Arg Met Ala Val Ala Leu Ile Cys
 260 265 270

Met Ser Met Glu Phe Gly Arg Ala Val Trp Leu Arg Phe His Pro Ser
 275 280 285

Ala Tyr Pro Pro Cys Pro His Pro Ser Phe Val Ala His Leu Gly Gly
 290 295 300

Val Ala Val Gly Ile Thr Leu Gly Val Val Val Leu Arg Asn Tyr Glu
 305 310 315 320

Gln Arg Leu Gln Asp Gln Ser Leu Trp Trp Ile Phe Val Ala Met Tyr
 325 330 335

Thr Val Phe Val Leu Phe Ala Val Phe Trp Asn Ile Phe Ala Tyr Thr
 340 345 350

Leu Leu Asp Leu Lys Leu Pro Pro Pro
 355 360

<210> 7
 <211> 19
 <212> PRT
 <213> Homo sapiens

<400> 7

Met Gly Arg Val Glu Asp Gly Gly Thr Thr Glu Glu Leu Glu Asp Trp
1 5 [REDACTED] 10 [REDACTED] 15 [REDACTED]
Asp Pro Gly

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number
WO 02/05843 A3

(51) International Patent Classification⁷: **C12N 15/85.**
A61K 39/395, 47/48, G01N 33/50, 33/68, A61P 35/00.
C07K 14/705, C12N 5/10

1049 Cortland Avenue, San Francisco, CA 94110 (US).
LI, Danxi [US/US]; 90 Behr Avenue, #32, San Francisco,
CA 94131 (US).

(21) International Application Number: PCT/US01/22555

(74) Agents: **ANDERTON, Tom** et al.; Exelixis, Inc., 170 Harbor Way, South San Francisco, CA 94083-0511 (US).

(22) International Filing Date: 18 July 2001 (18.07.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/219,289	19 July 2000 (19.07.2000)	US
60/277,471	21 March 2001 (21.03.2001)	US
60/277,487	21 March 2001 (21.03.2001)	US
60/304,863	12 July 2001 (12.07.2001)	US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): EX-ELIXIS, INC. [US/US]; 170 Harbor Way, P.O. Box 511, South San Francisco, CA 94083-0511 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **FRIEDMAN, Lori** [US/US]; One Bayside Village Place, Unit 212, San Francisco, CA 94107 (US). **LARSON, Jeffrey, S.** [US/US]; 1220 El Camino Real, #305, Burlingame, CA 94010 (US). **BELVIN, Marcia** [US/US]; 1619 Walnut Street, Apt. C, Berkeley, CA 94709 (US). **CHEN, Changyou** [US/US]; 6465 Crestwood Drive, Castro Valley, CA 94552 (US). **ROBERTSON, Stephanie, A.** [US/US]; 255 Fowler Avenue, San Francisco, CA 94127 (US). **LIOUBIN, Mario** [US/US]; 3014 Los Prados, #A310, San Mateo, CA 94403 (US). **SHI, Wen** [US/US]; 1324 8th Avenue, #4, San Francisco, CA 94112 (US). **CHAN, Jocelyn** [US/US];

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

6 June 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HUMAN RRP SEQUENCES AND METHODS OF USE

(57) Abstract: Rhomboid Related Proteins (RRPs), involved in the EGFR signaling pathway, are provided. Transgenic, nonhuman mammals containing a transgene encoding an RRP polypeptide or a gene effecting the expression of an RRP polypeptide, along with methods of modulating the interaction of RRP proteins with their pathway members, and methods of screening for agents that modulate the interaction of an RRP polypeptide with an RRP binding target, such as RRP-specific antibodies and small molecules identified in high throughput screens, are also provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein.

WO 02/05843 A3

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/85	A61K39/	A61K47/48	G01N33/50	G01N33/68
A61P35/00	C07K14/	C12N5/10		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EMBASE, WPI Data, PAJ, EPO-Internal, EMBL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J. PASCALL ET AL.: "Characterization of a mammalian cDNA encoding a protein with high sequence similarity to the Drosophila regulatory protein Rhomboid." FEBS LETTERS, vol. 429, no. 3, 16 June 1998 (1998-06-16), pages 337-340, XP004258029 Amsterdam, The Netherlands abstract figures 1,2 ---- -/-	1-28

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

7 March 2002

Date of mailing of the international search report

22/04/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	DATABASE EMBL 'Online' Accession Number Q9NX52, 1 October 2000 (2000-10-01) K. WATANABE ET AL.: "NEDO human cDNA sequencing project" XP002192453 abstract -----	14

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.